If I am reading the form 4 right, he could have waited until 2021 to exercise the option. Since there is no dividend, that would tell me he plans to sell the shares, but I don't know why he is waiting.
West, I am surprised at you. While it is always possible RCKY may be sold, there would be no need to amend the rights plan in a friendly sale, so the change has to be for corporate governance. This speculation is something to talk about I guess.
I haven't looked up their rights plan, but I think in general they are designed to prevent an acquirer acting WITHOUT management approval. My guess is that RCKY wants to show good governance for some reason.
My experience, based on a small sample, is that the Reuters "edited" transcripts tend to be better than the seeking alpha transcripts. Anyone have a different experience?
SPAN has good cash flow and dividends. On the other hand, checking Value Line, earnings have gone nowhere since 2007. I recall Skip commenting (about when I exited stock) that their sales were based on customer relationships rather than superior products/innovation or brand name or superior manufacturing (I hope I got that right). I believe they are up against bigger competitors. Management seems good, but getting closer to retirement. Stock is inexpensive, but not that cheap. It seems this is a company which needs to keep hustling to stay in place.
On the other hand, healthcare, with a focus on the aged, is a good industry to be in.
You might think it would be an easy beat, but this qtr wasn't, and they were almost giddy with their prospects.
I started looking at this stock but it has me very confused. In 2014 there are 3 reported eps: company reports GAAP of 1.32, company reports adjusted (for insurance) of .99, Value Line reports eps of 1.02.
I care, because I would like to know what recurring trailing 12 month earnings are. Recurring, in my mind, should be adjusted for discrete tax changes such as a change in the valuation allowance on previous tax losses.
.Anyone know what the number is? First half results are really good, but I have no feeling for how seasonal MGPI results are. You really can't look at historical earnings to estimate.
Could be that some info leaked. However, I often see rises before earnings come out on stocks, and I suspect it is driven by the type of investor who loves to talk about "dead money", and enjoys the excitement.
I was debating whether to buy shares, and the many intelligent posts, pro and con, were a definite help. One fact that bothered me: for the 6 months, watches were still 77% of sales. On the other hand, I recently read that Movado came up with the idea of having a second face, not exposed, for internet connected features. This could be a way to have a nice looking watch plus the functionality.
No, they aren't buying CASEY, but I always thought it was the ideal candidate. Good management, relatively stable business not likely subject to disruption, uses capital and could probably use much more for faster expansion if Berkshire owned it.
Picker, I'm not understanding your last post, since First Aid was included in ACU sales in the 2nd half of 2014 (acquired june 2, 2014).
I haven't looked at results closely, but EXCLUDED in calculating the (.11) per share loss were 244 million of provision for legal costs.
Good post, but "New emissions framework has bipartisan support " ?? You can't be referring to the President's latest proposal for power generation.